⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 1, 1988Journal of Clinical Oncology

Residual mass in lymphoma may not be residual disease.

George P. Canellos

View at Publisher

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1988.6.6.931 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3373263 Residual mass in lymphoma may not be residual disease. G P CanellosxG P CanellosSearch for articles by this author https://doi.org/10.1200/JCO.1988.6.6.931 First Page PDF © 1988 by American Society of Clinical Oncology

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

George P. Canellos (1988) studied this question.

synapsesocial.com/papers/6a1a43d5768e71e76eef2321 https://doi.org/10.1200/jco.1988.6.6.931

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Feasibility and Tolerability of Chemoimmunotherapy Given During Induction for Treatment of Patients With High-Risk Neuroblastoma: A Report From the Children's Oncology GroupJournal of Clinical Oncology · 2026
2Stereotactic Ablative Radiotherapy Versus Surgical Resection for Early-Stage Non–Small Lung Cancer: An Emulated Target TrialJournal of Clinical Oncology · 2026
3Immunochemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer: A Randomized Controlled TrialJournal of Clinical Oncology · 2026
4Methylphenidate for Hematologic Cancer–Related Fatigue: A Randomized Clinical TrialJournal of Clinical Oncology · 2026
5Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.4Journal of Clinical Oncology · 2026
6KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With Pembrolizumab for Unresected Stage I or II Non–Small Cell Lung CancerJournal of Clinical Oncology · 2026
7Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 StudyJournal of Clinical Oncology · 2026
8Art as a Shared Space: Tracing the Unseen Through a Body MapJournal of Clinical Oncology · 2026
9PARP Inhibitors in the Management of Ovarian Cancer: ASCO Living Guideline, Version 2026.1.0Journal of Clinical Oncology · 2026
10Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 TrialJournal of Clinical Oncology · 2026

More from Journal of Clinical Oncology